Lineage Cell Therapeutics (LCTX) Short Interest Ratio & Short Volume $0.99 -0.03 (-3.40%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$1.00 +0.02 (+1.80%) As of 08/1/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock Lineage Cell Therapeutics Short Interest DataLineage Cell Therapeutics (LCTX) has a short interest of 28.09 million shares. This marks a 1.26% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.5, indicating that it would take 12.5 days of the average trading volume of 1.55 million shares to cover all short positions.Current Short Interest28,090,000 sharesPrevious Short Interest27,740,000 sharesChange Vs. Previous Month+1.26%Dollar Volume Sold Short$28.09 millionShort Interest Ratio12.5 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares228,360,000 sharesPercentage of Shares Shorted12.30%Today's Trading Volume2,004,863 sharesAverage Trading Volume1,549,027 sharesToday's Volume Vs. Average129% Short Selling Lineage Cell Therapeutics? Sign up to receive the latest short interest report for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLCTX Short Interest Over TimeLCTX Days to Cover Over TimeLCTX Percentage of Float Shorted Over Time Lineage Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202528,090,000 shares $28.09 million +1.3%N/A12.5 $1.00 6/30/202527,740,000 shares $25.17 million -3.5%16.6%12.8 $0.91 6/15/202528,730,000 shares $23.29 million -2.3%17.2%17.1 $0.81 5/31/202529,410,000 shares $19.44 million -1.8%17.5%20.6 $0.66 5/15/202529,960,000 shares $14.10 million -0.1%17.8%22.2 $0.47 4/30/202530,000,000 shares $14.97 million +5.5%N/A23.4 $0.50 4/15/202528,430,000 shares $12.19 million +6.7%16.9%20.2 $0.43 3/31/202526,640,000 shares $12.03 million +19.3%15.8%17.1 $0.45 3/15/202522,340,000 shares $11.62 million +1.4%13.3%12.1 $0.52 2/28/202522,030,000 shares $12.37 million +2.2%13.1%11.8 $0.56 Get the Latest News and Ratings for LCTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202521,550,000 shares $0.00 +1.2%12.8%8.3 $0.00 1/31/202521,300,000 shares $0.00 -21.4%N/A8.3 $0.00 1/15/202527,110,000 shares $0.00 +4.2%N/A11.5 $0.00 12/31/202426,030,000 shares $0.00 +13.5%N/A12 $0.00 12/15/202422,940,000 shares $0.00 +25.1%N/A13.4 $0.00 11/30/202418,340,000 shares $0.00 +13.7%N/A13 $0.00 11/15/202416,130,000 shares $0.00 +1.2%N/A15.1 $0.00 10/31/202415,940,000 shares $0.00 +1.1%N/A36.8 $0.00 10/15/202415,770,000 shares $0.00 +3.6%N/A33.7 $0.00 9/30/202415,220,000 shares $0.00 -2.6%N/A32 $0.00 9/15/202415,630,000 shares $0.00 -1.2%N/A27.1 $0.00 8/31/202415,820,000 shares $0.00 +2.0%N/A25 $0.00 8/15/202415,510,000 shares $0.00 +6.5%N/A19.5 $0.00 7/31/202414,560,000 shares $0.00 No ChangeN/A16.6 $0.00 7/15/202414,560,000 shares $0.00 +12.7%N/A15.3 $0.00 6/30/202412,920,000 shares $0.00 No ChangeN/A12.8 $0.00 6/15/202412,920,000 shares $0.00 +5.4%N/A12 $0.00 5/31/202412,260,000 shares $0.00 -0.9%N/A11 $0.00 5/15/202412,370,000 shares $0.00 +13.5%N/A12.2 $0.00 4/30/202410,900,000 shares $0.00 +3.0%N/A11 $0.00 4/15/202410,580,000 shares $0.00 +1.7%N/A11.2 $0.00 3/31/202410,400,000 shares $0.00 +4.2%N/A11.4 $0.00 3/15/20249,980,000 shares $0.00 +3.7%N/A11.9 $0.00 2/29/20249,620,000 shares $0.00 -4.2%N/A11.5 $0.00 2/15/202410,040,000 shares $0.00 +18.7%N/A13.1 $0.00 1/31/20248,460,000 shares $0.00 +7.4%N/A11.3 $0.00 1/15/20247,880,000 shares $0.00 +13.5%N/A12.7 $0.00 12/31/20236,940,000 shares $0.00 +12.9%N/A11.3 $0.00 12/15/20236,150,000 shares $0.00 -3.5%N/A11.9 $0.00 11/30/20236,370,000 shares $0.00 +6.0%N/A13.4 $0.00He Called Nvidia at $1.10. Now, He Says THIS Stock Will… (Ad)The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.See his full breakdown of the seven stocks to own now 11/15/20236,010,000 shares $0.00 -2.3%N/A13.3 $0.00 10/31/20236,150,000 shares $7.01 million -2.5%N/A14.1 $1.14 10/15/20236,310,000 shares $0.00 +1.5%N/A14.2 $0.00 9/30/20236,220,000 shares $0.00 No ChangeN/A13.2 $0.00 9/15/20236,220,000 shares $0.00 +0.7%N/A13.3 $0.00 8/31/20236,180,000 shares $0.00 +1.0%N/A8.1 $0.00 8/15/20236,120,000 shares $0.00 -0.3%N/A7.8 $0.00 7/31/20236,140,000 shares $0.00 -3.6%N/A8.1 $0.00 7/15/20236,370,000 shares $0.00 -1.1%N/A8.6 $0.00 6/30/20236,440,000 shares $0.00 +19.0%N/A9 $0.00 6/15/20235,410,000 shares $0.00 +13.7%N/A7.7 $0.00 5/31/20234,760,000 shares $0.00 +11.5%N/A12.7 $0.00 5/15/20234,270,000 shares $0.00 -6.0%N/A12.8 $0.00 4/30/20234,540,000 shares $0.00 -0.2%N/A12.9 $0.00 4/15/20234,550,000 shares $0.00 +2.9%N/A13 $0.00 3/31/20234,420,000 shares $0.00 +7.3%N/A12.9 $0.00 3/15/20234,120,000 shares $0.00 -1.2%N/A10.9 $0.00 2/28/20234,170,000 shares $0.00 -0.5%N/A11.2 $0.00 2/15/20234,190,000 shares $0.00 +1.0%N/A11.3 $0.00 1/31/20234,150,000 shares $0.00 -0.2%N/A10.5 $0.00 1/15/20234,160,000 shares $0.00 +2.0%N/A10.9 $0.00 12/30/20224,080,000 shares $0.00 -4.0%N/A10.5 $0.00 12/15/20224,250,000 shares $0.00 -1.6%N/A12.5 $0.00 11/30/20224,320,000 shares $0.00 +0.7%N/A13.4 $0.00 11/15/20224,290,000 shares $0.00 -0.2%N/A13.8 $0.00 10/31/20224,300,000 shares $0.00 -3.4%N/A15 $0.00 10/15/20224,450,000 shares $0.00 -0.5%N/A13.9 $0.00 9/30/20224,470,000 shares $0.00 +0.7%N/A14.2 $0.00 9/15/20224,440,000 shares $0.00 -2.8%N/A6.6 $0.00 8/31/20224,570,000 shares $0.00 +2.0%N/A6 $0.00 8/15/20224,480,000 shares $0.00 -7.4%N/A5.3 $0.00 7/31/20224,840,000 shares $0.00 -2.6%N/A5.3 $0.00 7/15/20224,970,000 shares $0.00 -9.3%N/A5.3 $0.00 6/30/20225,480,000 shares $0.00 -38.6%N/A5.4 $0.00 6/15/20228,930,000 shares $0.00 -7.8%N/A8.9 $0.00 5/31/20229,690,000 shares $0.00 -8.3%N/A14 $0.00 5/15/202210,570,000 shares $0.00 +5.0%N/A15.7 $0.00 4/30/202210,070,000 shares $0.00 +12.5%N/A15.7 $0.00 4/15/20228,950,000 shares $0.00 -3.8%N/A13.3 $0.00 3/31/20229,300,000 shares $0.00 +1.8%N/A13 $0.00 3/15/20229,140,000 shares $0.00 +5.2%N/A10.3 $0.00 2/28/20228,690,000 shares $0.00 -3.3%N/A7.6 $0.00 2/15/20228,990,000 shares $0.00 +4.9%N/A7.3 $0.00 1/31/20228,570,000 shares $13.54 million +0.2%N/A6.9 $1.58 1/15/20228,550,000 shares $0.00 +7.7%N/A6.9 $0.00 12/31/20217,940,000 shares $0.00 -23.3%N/A7.1 $0.00 12/15/202110,350,000 shares $0.00 +23.7%N/A9.8 $0.00 11/30/20218,370,000 shares $18.92 million +9.3%N/A10.5 $2.26 11/15/20217,660,000 shares $0.00 -6.6%N/A10.8 $0.00 10/29/20218,200,000 shares $18.70 million No ChangeN/A12.1 $2.28He Called Nvidia at $1.10. Now, He Says THIS Stock Will… (Ad)The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.See his full breakdown of the seven stocks to own now 10/15/20218,200,000 shares $0.00 -6.8%N/A12.6 $0.00 9/30/20218,800,000 shares $0.00 +14.3%N/A12.4 $0.00 9/15/20217,700,000 shares $0.00 +1.1%N/A7.4 $0.00 8/31/20217,620,000 shares $0.00 -6.6%N/A7.2 $0.00 8/13/20218,160,000 shares $0.00 -8.0%N/A6.6 $0.00 7/30/20218,870,000 shares $0.00 -2.0%N/A6.8 $0.00 7/15/20219,050,000 shares $0.00 +6.2%5.6%6.4 $0.00 6/30/20218,520,000 shares $0.00 +37.2%5.3%6 $0.00 6/15/20216,210,000 shares $0.00 -3.1%3.9%5.4 $0.00 5/28/20216,410,000 shares $0.00 +2.7%4.0%5.4 $0.00 5/14/20216,240,000 shares $0.00 +13.0%N/A5.2 $0.00 4/30/20215,520,000 shares $0.00 +1.7%N/A3.7 $0.00 4/15/20215,430,000 shares $13.68 million +1.9%N/A3.5 $2.52 3/31/20215,330,000 shares $13.86 million +25.4%N/A2.9 $2.60 3/15/20214,250,000 shares $10.24 million +10.4%N/A2.2 $2.41 2/26/20213,850,000 shares $9.09 million -14.6%2.6%2 $2.36 2/12/20214,510,000 shares $10.19 million -2.0%3.0%2.6 $2.26 1/29/20214,600,000 shares $11.27 million -23.1%3.1%2.9 $2.45 1/15/20215,980,000 shares $17.46 million +7.4%4.0%4.2 $2.92 12/31/20205,570,000 shares $9.69 million -10.7%3.7%4.9 $1.74 12/15/20206,240,000 shares $11.42 million -12.9%4.2%6.1 $1.83 11/30/20207,160,000 shares $10.02 million +1.0%4.8%8.2 $1.40 11/15/20207,090,000 shares $10.42 million -10.8%4.8%8.7 $1.47 10/30/20207,950,000 shares $9.22 million -2.6%5.3%10.6 $1.16 10/15/20208,160,000 shares $11.18 million +12.4%5.5%10.7 $1.37 9/30/20207,260,000 shares $6.80 million +28.0%4.9%10.2 $0.94 9/15/20205,670,000 shares $5.33 million -9.1%3.8%5.9 $0.94 8/31/20206,240,000 shares $5.71 million +7.8%4.2%6.1 $0.92 8/14/20205,790,000 shares $5.33 million -3.8%3.9%4.5 $0.92 LCTX Short Interest - Frequently Asked Questions What is Lineage Cell Therapeutics' current short interest? Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 28,090,000 shares of LCTX short. Learn More on Lineage Cell Therapeutics' current short interest. What is a good short interest ratio for Lineage Cell Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LCTX shares currently have a short interest ratio of 12.0. Learn More on Lineage Cell Therapeutics's short interest ratio. Is Lineage Cell Therapeutics' short interest increasing or decreasing? Lineage Cell Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 28,090,000 shares, an increase of 1.3% from the previous total of 27,740,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Lineage Cell Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lineage Cell Therapeutics: Nurix Therapeutics, Inc. (18.25%), uniQure N.V. (15.75%), Syndax Pharmaceuticals, Inc. (27.53%), Basilea Pharmaceutica AG (0.06%), Trevi Therapeutics, Inc. (8.48%), Xeris Biopharma Holdings, Inc. (12.50%), Niagen Bioscience, Inc. (4.29%), Nuvation Bio Inc. (31.53%), Cronos Group Inc. (1.27%), KalVista Pharmaceuticals, Inc. (18.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Lineage Cell Therapeutics stock? Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. LCTX shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lineage Cell Therapeutics? A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further. How often is Lineage Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies GPCR Short Interest Data ARDX Short Interest Data COLL Short Interest Data VERV Short Interest Data ORIC Short Interest Data CURLF Short Interest Data PROK Short Interest Data IMNM Short Interest Data ZYME Short Interest Data AKBA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSEAMERICAN:LCTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LCTX Stock Alerts